Previous Article | Next Article 
Journal of Clinical Microbiology, February 1999, p. 413-416, Vol. 37, No. 2
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Vancomycin-Resistant Enterococcus faecium Colonization
in Children
Nalini
Singh-Naz,1,2,3,*
Ambreen
Sleemi,4
Andreas
Pikis,1,5
Kantilal M.
Patel,2,6 and
Joseph M.
Campos2,7,8,9
Departments of Infectious
Diseases1 and
Laboratory
Medicine,7 and
Center for Health
Services and Clinical Research, Children's Research
Institute,6 Children's National Medical Center,
and
Departments of Pediatrics,2
Pathology,8 and
Microbiology/Immunology,9 and
School of Public Health,3 George
Washington University School of Medicine, Washington, D.C.;
Department of Obstetrics and Gynecology, Louisiana State
University Medical Center, New Orleans,
Louisiana4; and
Oral Infection and
Immunity Branch, National Institute of Dental and Craniofacial
Research, National Institutes of Health, Bethesda,
Maryland5
Received 4 September 1998/Returned for modification 13 October
1998/Accepted 12 November 1998
 |
ABSTRACT |
Nosocomial vancomycin-resistant Enterococcus (VRE)
infections have been described in only small numbers of pediatric
patients. In none of these studies were multivariate analyses performed to assess which factors were independent risk factors in these patients. In the present cohort study of patients admitted to our
hematology/oncology unit, surveillance cultures revealed a colonization
rate of 24% and all isolates were identified as Enterococcus faecium. Risk factors associated with colonization with VRE
identified by multiple logistic regression analysis included young age
and chemotherapy with antineoplastic agents, cefotaxime, vancomycin, and ceftazidime. A molecular epidemiological tool, pulsed-field gel
electrophoresis, was used to determine the relatedness of the VRE
isolates detected. DNA analysis by this method identified two major
clusters of VRE isolates. Young children with gastrointestinal colonization with VRE, without evidence of clinical infection, can
serve as a reservoir for the spread of VRE.
 |
INTRODUCTION |
The evolution of antimicrobial
resistance has become a global problem (2, 5, 20).
Analysis from the National Nosocomial Infections Surveillance system at
the Centers for Disease Control and Prevention has demonstrated a
20-fold increase in nosocomial infections due to vancomycin-resistant
enterococci (VRE) (4). This development limits the
therapeutic options for treating serious infections (15).
Acquisition of antimicrobial resistance by enterococci can be
facilitated by interstrain spread of conjugative transposons,
pheromone-responsive plasmids, and broad-host-range plasmids (18).
Nosocomial VRE infections have been described frequently in adult
intensive care patients (3, 7, 9, 14, 16, 23, 25). However,
VRE infections have been reported in only small numbers of pediatric
patients (1, 10, 21). In none of these studies were
multivariate analyses performed to identify independent risk factors in
these patients. Young children colonized gastrointestinally with VRE
may transmit this organism by fecal-oral spread and by contamination of
their environment. The purpose of the present study was to determine
the risk factors associated with VRE colonization in hospitalized
children by using univariate and multiple logistic regression analyses.
In addition, a molecular epidemiological tool was employed to establish
the relatedness of the VRE isolates detected.
On 21 June 1994, a blood culture collected from a bone marrow
transplant recipient yielded the first VRE identified at Children's National Medical Center (CNMC). This finding prompted an investigation of the prevalence of VRE colonization among high-risk patients at our
institution
a multidisciplinary, regional referral center.
 |
MATERIALS AND METHODS |
Study design.
Surveillance was conducted between 1 August
and 20 October 1994 in our hematology/oncology (H/O) unit during an
investigation of the circumstances surrounding the index case described
above. The goal of this cohort study was to determine the prevalence of
VRE colonization in our H/O unit. The H/O unit at CNMC has 27 beds,
including 6 in individual positive-pressure rooms (intended for bone
marrow transplant patients) and 5 in individual rooms reserved for
other patients. The remaining beds are located within rooms containing
two beds. One hundred twenty-five patients were admitted to the H/O
unit during the surveillance period. The purpose of the surveillance
cultures was explained to the patients and their parents, and specimens
were collected on admission or soon thereafter. The majority of
patients had an underlying diagnosis of malignancy or sickle cell
disease. This unit also served as an overflow unit for a small number
of acute care patients. Data collected from each patient included age,
gender, weight, and admitting or underlying diagnosis on the day of
admission. Diagnoses were categorized by ICD9 code. The remaining
variables (e.g., antimicrobial agent administration prior to specimen
collection, use of invasive devices, operative status, number of
hospitalizations within the prior year, immune system status, and
length of hospitalization) were assessed prior to culture. Information
from patient medical records was recorded on a standardized data form.
History of antimicrobial agent administration prior to specimen
collection was obtained from patients before admission and from patient
medical records while at the hospital. Some antimicrobial agent
administration histories prior to hospital encounter may have been
incomplete due to poor recollection by patients. A history of use
included agents given for infectious disease prophylaxis or agents
administered in the emergency department prior to admission. The use of
vancomycin, ceftazidime, cefotaxime, and other commonly prescribed
antimicrobial agents were analyzed as independent variables.
Invasive device use was defined as placement of a central venous line,
a Foley catheter, or mechanical ventilation prior to specimen
collection. All patients had peripheral intravenous lines placed prior
to culture collection.
Immunosuppressed status was defined by the following criteria:
administration of antineoplastic therapy within 6 months of specimen
collection, bone marrow transplantation prior to culture, or an
absolute neutrophil count of <500 per mm3. Operative
procedure status was considered relevant when documentation of an
operating room procedure during the same admission prior to specimen
collection was present in the medical record. These procedures included
Broviac line placements and tumor debulking procedures.
Microbiological methods.
Colonization with VRE was
determined from rectal swabs obtained on admission to the H/O unit or
from weekly surveillance cultures of rectal swabs obtained from
patients hospitalized on the unit. Rectal swabs from all active H/O
patients were cultured at least once. Rectal swabs were inoculated onto
Campy blood agar with 10 µg of vancomycin (Campy BAP; Becton
Dickinson, Cockeysville, Md.) per ml (6). Any growth or haze
on the medium surface after 24 to 48 h of incubation at 35°C in
ambient air was considered an indication of resistance to vancomycin.
Suspicious nonhemolytic or alpha-hemolytic colonies were Gram stained
to rule out the presence of Lactobacillus spp. Gram-positive
cocci were tentatively identified as Enterococcus spp. with
a negative catalase test and a positive pyrrolidonyl arylamidase test.
Species identification was determined with the MicroScan WalkAway
instrument (Positive Breakpoint Combo Panel Type 6; Dade MicroScan,
West Sacramento, Calif.). Only one isolate per patient was studied.
MICs of vancomycin and other antimicrobial agents were also determined
with the MicroScan WalkAway instrument. Panels were
inoculated with
turbidity-standardized suspensions prepared from
overnight cultures of
isolates characterized as resistant when
cultured on Campy BAP. Panels
were incubated for 24 h at 35°C
and read by the MicroScan
WalkAway instrument. Isolates were categorized
as susceptible,
intermediate, or resistant to antimicrobial agents
in accordance with
criteria published by the National Committee
for Clinical Laboratory
Standards (
19).
DNA analysis by pulsed-field gel electrophoresis (PFGE) was also
performed. Genomic DNA from 30 VRE isolates was prepared
for digestion
and electrophoresis as described previously (
7).
In brief,
after digestion with the restriction endonuclease
SmaI,
chromosomal DNA fragments were separated with a contour-clamped
homogenous electric field unit (CHEF-DR II; Bio-Rad Laboratories,
Hercules, Calif.) and applied to agarose gels. The gels were stained
with ethidium bromide and photographed. Gel patterns were compared,
and
isolates were categorized as indistinguishable, closely related,
possibly related, or different in accordance with the criteria
for
interpreting PFGE patterns of Tenover et al. (
24).
Environmental cultures of swabs of the sink, bed rail, countertop,
over-bed table, and room-exiting doorknob were performed
in colonized
patient rooms before and after discharge. Dacron-tipped
swabs were
moistened with sterile Trypticase soy broth and used
to sample a
1-cm
2 area of the appropriate
surfaces.
Statistical methods.
The Kruskal-Wallis test for continuous
variables and Fisher's exact test for categorical variables were used
for univariate comparisons of variables between patients who were VRE
positive and those who were not (11, 12). A significance
level of <0.05 was chosen. Odds ratios and 95% confidence intervals
were determined for each of the variables. Multiple logistic regression
analysis was performed on variables that were statistically significant during the univariate analysis. Selection of variables was done by
first performing a Fisher's exact test or t test for each
binary variable or continuous variable. A significance level of P
of <0.30 was chosen as a cutoff. The multiple logistic regression model was developed by using forward and backward subtraction, and the
model was checked for multicollinearity. The SAS/STAT software (SAS
Institute Inc., Cary, N.C.) was used for univariate and multivariate
analysis (22).
 |
RESULTS |
One hundred twenty-five children were admitted to the H/O unit
between 1 August and 20 October 1994. Two patients refused surveillance
cultures. Of the 123 children who were cultured for VRE, 30 were
positive in addition to the index case (colonization rate, 24%).
Twenty-six of the cultured children had incomplete medical record
information and were excluded from the analysis, leaving a study sample
size of 97 patients. Of the 26 patients with incomplete records, only
one was colonized with VRE. The patients with missing records did not
differ significantly from those in the study sample with respect to
their demographic characteristics. Of the 97 study patients (30 VRE
positive and 67 VRE negative), 46 had an underlying diagnosis of
malignancy, 40 had sickle cell disease, and 11 had other diagnoses.
During the surveillance period, one patient colonized with VRE
developed VRE bacteremia while undergoing total body irradiation and
chemotherapy as a prelude to bone marrow transplantation. During the
first 3 weeks of October, 43 patients had surveillance cultures
performed, with only one positive culture resulting. By that time, all
current H/O unit patients had had surveillance cultures performed at
least once. No additional cases of VRE infection or intestinal
colonization were recognized after 20 October 1994, and surveillance
cultures were discontinued. All of the environmental cultures were negative.
Among the 30 VRE-positive and 67 VRE-negative children, the risk
factors associated by univariate analysis with VRE colonization were
young age, use of invasive devices, administration of antimicrobial therapy, immunosuppression, and an underlying diagnosis of malignancy or sickle cell disease (Table 1). Several
of these risk factors are surrogate markers for frequent
hospitalization. The multiple logistic regression analysis using
variables from Table 1 is shown in Table
2. After controlling for other risk
variables, our analysis showed that young patients who were given
antineoplastic chemotherapy, cefotaxime, vancomycin, or ceftazidime
prior to surveillance cultures had 10-, 38-, 50-, or 96-fold higher
risks of VRE positivity, respectively (Table 2). The risk coefficients for patients receiving cefotaxime and vancomycin or ceftazidime and
vancomycin were not additive.
All of the isolates that appeared to be vancomycin resistant on Campy
BAP were determined to be resistant with the MicroScan WalkAway
instrument (MIC, >32 µg/ml). All VRE isolates were
Enterococcus faecium and were resistant to several other
antimicrobial agents. However, all were susceptible to chloramphenicol
and the high-level gentamicin synergy test and all but one were
susceptible to tetracycline. Susceptibility to teicoplanin was not determined.
PFGE was performed on 30 of the VRE isolates. The PFGE patterns for 28 of the 30 isolates are shown in Fig. 1.
Heterogeneity in these isolates was present. Fourteen different PFGE
patterns were discerned. However, two pattern clusters encompassed 57% of the isolates tested: pattern cluster 1 encompassed 6 isolates (Fig.
1, lanes 1, 5, 16, 18, 24, and 28), pattern cluster 2 encompassed 10 isolates (lanes 4, 6, 9, 11, 12, 13, 17, 19, 22, and 27), pattern cluster 3 encompassed 2 isolates (lanes 2 and 26), and pattern cluster
4 encompassed 2 isolates (lanes 3 and 20). The remaining 8 isolates at
best were possibly related. There was only a low-level correlation
between the restriction endonuclease patterns and the antimicrobial
agent resistance patterns.

View larger version (102K):
[in this window]
[in a new window]
|
FIG. 1.
PFGE of 28 of the 30 VRE isolates. There were two major
clusters by SmaI restriction endonuclease patterns (clusters
1 and 2). Lanes 1, 5, 16, 18, 24, and 28, pattern cluster 1 (6 isolates); lanes 4, 6, 9, 11, 12, 13, 17, 19, 22, and 27, pattern
cluster 2 (10 isolates); lanes 2 and 26, pattern cluster 3 (2 isolates); and lanes 3 and 20, pattern cluster 4 (2 isolates). The
remaining 10 isolates could represent possibly related strains.
|
|
 |
DISCUSSION |
In this study, a molecular epidemiological technique revealed the
existence of multiple clusters of genetically related VRE isolates in
our patient population. PFGE yielded several different patterns for the
30 isolates that were tested. Two PFGE patterns predominated among the
isolates, suggesting patient-to-patient spread of VRE within this
cohort of patients. There was no correlation between the rooms to which
patients were admitted during the current admission and the PFGE
patterns. One can speculate that dissemination of VRE strains within
these cohorts occurred during previous admissions, since recurrent
hospitalization is frequent among high-risk H/O patients. In the United
States, most acquisition of VRE occurs in the hospital. This is in
contrast to the published experience in Europe, where
community-acquired infections have been described (8).
Little if any relation could be established between restriction endonuclease patterns and patterns of antimicrobial agent resistance.
We also identified a 24% carrier rate and risk factors associated with
this carriage. Multivariate analysis indicated that VRE-colonized
patients were young, tended to have received prior antimicrobial
therapy, and were immunosuppressed. Our results are in keeping
with those from a study of pediatric oncology patients in which
neutropenia, exposure to broad-spectrum antimicrobial agents, and
administration of vancomycin were important risk factors (10). Multiple logistic regression analysis of our data
found, however, that ceftazidime therapy preceded VRE colonization more often than vancomycin therapy did (odds ratio, 95.6 versus 50.4). The
same analysis revealed that administration of cancer chemotherapeutic agents within the previous 6 months also increased the risk of VRE
colonization. During the surveillance period, one of our patients experienced VRE bacteremia while receiving chemotherapy in preparation for a bone marrow transplant. Intestinal tract colonization with VRE
may put patients with malignancies at risk for VRE bacteremia, especially during neutropenic episodes (10).
The Hospital Infection Control Practices Advisory Committee guidelines
on prevention and control of the spread of VRE were implemented in our
H/O unit once patients were identified as colonized (13).
Parents, family members, and staff were given VRE fact sheets, and the
importance of observing infection prevention and control measures was
emphasized. Because the gastrointestinal tract can remain colonized
with VRE for prolonged periods without clinically apparent disease,
early identification of infected patients is critical, especially when
dealing with young children with poor hygiene who are prone to
fecal-oral spread of microorganisms.
 |
ACKNOWLEDGMENTS |
We acknowledge the helpful suggestions of William Rodriguez. We
thank Bruce Sprague of the CNMC Center for Health Services and Clinical
Research for his help with data management; Eileen Cantwell, Judy
Miles, and Dorleen Brown of the Hospital Epidemiology Department; and
the staff of the H/O unit at the Children's National Medical Center,
Washington, D.C.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infectious Diseases, Children's National Medical Center, 111 Michigan Ave., NW, Washington, DC 20010. Phone: (202) 884-3956. Fax: (202) 884-3850. E-mail: nsingh{at}cnmc.org.
 |
REFERENCES |
| 1.
|
Bingen, E. H.,
E. Denamur,
N. Y. Lambert-Zechovsky, and J. Elion.
1991.
Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital.
J. Clin. Microbiol.
29:1888-1892[Abstract/Free Full Text].
|
| 2.
|
Boyce, J. M.
1997.
Vancomycin-resistant enterococcus: detection, epidemiology, and control measures.
Infect. Dis. Clin. N. Am.
11:367-384[Medline].
|
| 3.
|
Boyle, J. F.,
S. A. Soumakis,
A. Rendo,
J. A. Herrington,
D. G. Gianarkis,
B. E. Thurberg, and B. G. Painter.
1993.
Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci.
J. Clin. Microbiol.
31:1280-1285[Abstract/Free Full Text].
|
| 4.
|
Centers for Disease Control and Prevention: Project ICARE Intensive Care Antimicrobial Resistance Epidemiology.
1998.
Unpublished data
National Nosocomial Infection System.
|
| 5.
|
Chenworth, C., and D. Schaberg.
1990.
The epidemiology of enterococci.
Eur. J. Clin. Microbiol. Infect. Dis.
9:80-89[Medline].
|
| 6.
|
Edberg, S. C.,
C. J. Hardalo,
C. Kontnick, and S. Campbell.
1994.
Rapid detection of vancomycin-resistant enterococci.
J. Clin. Microbiol.
32:2182-2184[Abstract/Free Full Text].
|
| 7.
|
Edmond, M. B.,
J. F. Ober,
D. L. Weinbaum,
M. A. Pfaller,
T. Hwang,
M. D. Sanford, and R. P. Wenzel.
1995.
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.
Clin. Infect. Dis.
20:1126-1133[Medline].
|
| 8.
|
Endtz, H. P.,
N. Van Den Braak,
A. Van Belkum,
J. A. J. W. Kluytmans,
J. G. M. Koeleman,
L. Spanjaard,
A. Voss,
A. J. L. Weersink,
C. M. J. E. Vandenbroucke-Grauls,
A. G. M. Buiting,
A. Van Duin, and H. A. Verbrugh.
1997.
Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.
J. Clin. Microbiol.
35:3026-3031[Abstract].
|
| 9.
|
Handwerger, S.,
B. Raucher,
D. Altarac,
J. Monka,
S. Marchione,
K. V. Singh,
B. E. Murray,
J. Wolf, and B. Walters.
1993.
Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.
Clin. Infect. Dis.
16:750-755[Medline].
|
| 10.
|
Henning, K. J.,
H. Delencastre,
J. Eagan,
N. Boone,
A. Brown,
M. Chung,
N. Wollner, and D. Armstrong.
1996.
Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection.
Pediatr. Infect. Dis. J.
15:848-854[Medline].
|
| 11.
|
Hirsch, R. P., and R. K. Riegelman.
1996.
Statistical operations: analysis of health care research data, p. 270-274.
, 326-330. Blackwell Science, Inc., Cambridge, Mass.
|
| 12.
|
Hosmer, D. W., and S. Lemeshow.
1989.
Applied logistic regression, p. 25-34.
John Wiley & Sons, Inc., New York, N.Y.
|
| 13.
|
Hospital Infection Control Practices Advisory Committee (HICPAC).
1995.
Recommendation for preventing the spread of vancomycin resistance.
Infect. Control Hosp. Epidemiol.
16:105-113[Medline].
|
| 14.
|
Karanfil, L. V.,
M. Murphy,
A. Josephson,
R. Gaynes,
L. Mandel,
B. C. Hill, and J. M. Swenson.
1992.
A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit.
Infect. Control Hosp. Epidemiol.
13:195-200[Medline].
|
| 15.
|
Moellering, R. C.
1991.
The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options.
J. Antimicrob. Chemother.
28:1-12[Free Full Text].
|
| 16.
|
Morris, J. G.,
D. K. Shay,
J. N. Hebden,
R. J. McCarter,
B. E. Perdue,
W. Jarvis,
J. A. Johnson,
T. C. Dowling,
L. B. Polish, and R. S. Schwalbe.
1995.
Enterococci resistant to multiple antimicrobial agents, including vancomycin.
Ann. Intern. Med.
123:250-259[Abstract/Free Full Text].
|
| 17.
|
Murray, B. E.,
K. V. Singh,
J. D. Heath,
B. R. Sharma, and G. M. Weinstock.
1990.
Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites.
J. Clin. Microbiol.
28:2059-2063[Abstract/Free Full Text].
|
| 18.
|
Murray, B. E.
1998.
Diversity among multidrug-resistant enterococci.
Emerg. Infect. Dis.
4:1-14[Medline].
|
| 19.
|
National Committee for Clinical Laboratory Standards.
1998.
Performance standards for antimicrobial susceptibility testing; eighth informational supplement. NCCLS document M100-S8.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 20.
|
Rice, L. B., and D. M. Shales.
1995.
Vancomycin resistance in the enterococcus: relevance in pediatrics.
Pediatr. Clin. N. Am.
42:601-617[Medline].
|
| 21.
|
Rubin, L. G.,
E. C. Tucci,
E. Cercenado,
G. Eliopoulos, and H. D. Isenberg.
1992.
Vancomycin-resistant Enterococcus faecium in hospitalized children.
Infect. Control Hosp. Epidemiol.
13:700-705[Medline].
|
| 22.
|
SAS Institute.
1990.
SAS/STAT user's guide, version 6, 4th ed, vol. 2. , p. 1071-1126.
SAS Institute, Cary, N.C.
|
| 23.
|
Stroud, L.,
J. Edwards,
L. Danzig,
D. Culver, and R. Gaynes.
1996.
Risk factors for mortality associated with enterococcal bloodstream infections.
Infect. Control Hosp. Epidemiol.
17:576-580[Medline].
|
| 24.
|
Tenover, F. C.,
R. D. Arbeit,
G. Goering,
P. A. Mickelsen,
B. E. Murray,
D. H. Persing, and B. Swaminathan.
1995.
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.
J. Clin. Microbiol.
33:2233-2239[Medline].
|
| 25.
|
Weinstein, J. W.,
R. Roe,
M. Towns,
L. Sanders,
J. J. Thorpe,
G. R. Corey, and D. J. Sexton.
1996.
Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital.
Infect. Control Hosp. Epidemiol.
17:36-41[Medline].
|
Journal of Clinical Microbiology, February 1999, p. 413-416, Vol. 37, No. 2
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Harbarth, S., Cosgrove, S., Carmeli, Y.
(2002). Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother.
46: 1619-1628
[Full Text]
-
Kobayashi, K., Rao, M., Keis, S., Rainey, F. A., Smith, J. M. B., Cook, G. M.
(2000). Enterococci with reduced susceptibility to vancomycin in New Zealand. J Antimicrob Chemother
46: 405-410
[Abstract]
[Full Text]
-
BARNAUD, G., BINGEN, E.
(2000). Genotypic characterisation of endemic VanA Enterococcus faecium strains isolated in a paediatric hospital. J Med Microbiol
49: 793-799
[Abstract]
[Full Text]
-
Bischoff, W. E., Reynolds, T. M., Hall, G. O., Wenzel, R. P., Edmond, M. B.
(1999). Molecular Epidemiology of Vancomycin-Resistant Enterococcus faecium in a Large Urban Hospital over a 5-Year Period. J. Clin. Microbiol.
37: 3912-3916
[Abstract]
[Full Text]